Manufacturing, latest filing in June 2026

On June 5, 2026, the 3M Company ("3M") Board of Directors ("Board") elected Jennifer W. Rumsey to 3M's Board and appointed Ms. Rumsey to the Science, Technology and Sustainability Committee of the Board, each effective June 5, 2026.

On June 2, 2026, Mr. Jan Vleugals, Chief Operating Officer International of Alliance Laundry Holdings Inc. (the "Company"), provided notice of his decision to retire effective as of September 30, 2026, following more than a decade of distinguished service.

Also stated in this filing

• The Board of Directors of the Company will appoint Bob Calver as Chief Operating Officer International, effective October 1, 2026, following Mr. Vleugals' retirement.

On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the "Board") of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company's 2026 annual meeting of stockholders (the "2026 Annual Meeting").

Also stated in this filing

• Neither Mr. Jellison's decision nor Dr. Larsen's decision to resign involved any disagreement with the Company, its management or the Board.
• The Board accepted both Mr. Jellison's and Dr. Larsen's resignations and in connection therewith, effective at the 2026 Annual Meeting, the Board will decrease the size of the Board from nine to seven members.

On June 22, 2026, Dr. Randal W. Scott notified BridgeBio Pharma, Inc. (the "Company"), of his resignation as a member of the Board of Directors of the Company (the "Board") upon the completion of his term as a Class I director, effective as of June 22, 2026, the date of the Company's 2026 Annual Meeting of Stockholders (the "Annual Meeting").

Also stated in this filing

• Dr. Scott's resignation was not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

(b) On June 11, 2026, Stephen Reitman expressed his intention to not stand for re-election to the Board of Directors of Capri Holdings Limited (the "Company") at the 2026 Annual Meeting of Shareholders (the "2026 Annual Meeting") of the Company, and his term will therefore end at the conclusion of the 2026 Annual Meeting on July 29, 2026 (subject to any adjournment or postponement thereof).

Also stated in this filing

• Mr. Reitman is retiring and his determination to not stand for re-election is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

On April 6, 2026, Krista McDonough, Chief Legal and Sustainability Officer of Capri Holdings Limited (the "Company"), notified the Company of her decision to voluntarily resign from her position in order to pursue another professional opportunity.

Also stated in this filing

• Ms. McDonough's resignation will be effective June 26, 2026.
• The Company has initiated a process to identify her successor.

On October 23, 2026, Christopher T. Hatto, Vice President, Global Business Solutions and Chief Accounting Officer of General Motors Company (the "Company"), notified the Company of his decision to retire, effective April 1, 2027 (the "Retirement Date").

Also stated in this filing

• Mr. Hatto's decision to retire is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
• Mr. Hatto will continue to serve as the Company's principal accounting officer through the Retirement Date to support an orderly transition.
• The Company will announce the appointment of a successor principal accounting officer at a later date.

On May 26, 2026, Jonathan McNeill, a member of the Board of Directors (the "Board") of General Motors Company (the "Company"), notified the Board that he will not stand for reelection as a director at the Company's 2026 Annual Meeting of Shareholders to be held on June 2, 2026 (the "Annual Meeting") and will retire from the Board upon the conclusion of the Annual Meeting.

Also stated in this filing

• Mr. McNeill's retirement is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
• The Company is grateful for Mr. McNeill's service on the Board and his contributions over the years.
• In connection with Mr. McNeill's departure, the Board intends to reduce its size from 11 directors to 10 directors after the Annual Meeting.

On March 31, 2026, Dan Whalen notified Harmonic Inc. of his resignation from Harmonic's Board of Directors (the "Board"), effective March 31, 2026, due to potential conflicts of interest that may arise from his acceptance of a new role at another company.

Also stated in this filing

• Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
• Mr. Whalen's resignation was not the result of any disagreement with Harmonic on any matter relating to Harmonic's operations, policies or practices.
• Mr. Whalen has served as a member of the Board since 2024, after previously serving from 2021 to 2023, and also served as a member of the Audit Committee and Compensation Committee.
• Harmonic thanks Mr. Whalen for his years of service and valuable contributions to the company.

On June 16, 2026, the Board of Directors (the "Board") of Illumina, Inc. (the "Company") increased the size of the Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., to serve on the Board, effective immediately.

Also stated in this filing

• Dr. Skovronsky will stand for election at the Company's 2027 annual meeting of stockholders to serve for a one-year term commencing with such meeting.
• Dr. Skovronsky qualifies as an independent director under the applicable rules of The Nasdaq Stock Market and the Securities and Exchange Commission.
• Dr. Skovronsky will participate in the non-employee director compensation programs described under "Director Compensation" in the Company's proxy statement filed on April 9, 2026.

Frances Arnold, Robert S. Epstein and Gary S. Guthart notified the Board of Directors (the "Board") of Illumina, Inc. (the "Company") of her or his intention to retire as a director of the Company, effective as of May 21, 2026 (the date of the Company's 2026 annual meeting of stockholders).

Also stated in this filing

• (b) On April 2, 2026, each of Drs.
• Arnold, Epstein and Guthart are not the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies or practices of the Company.

O n October 31, 2026 , the Board of Directors (the "Board") of The Kraft Heinz Company (the "Company") appointed Kelly M. Dilts and J. Michael Schlotman as members of the Board, effective as November 4, 2026.

On October 2, 2026, Angel S. Willis, Executive Vice President, Global General Counsel and Corporate Affairs Officer, notified The Kraft Heinz Company (the "Company") that she has decided to resign from her position with the Company, effective October 20, 2026, to pursue other opportunities. 1

On June 18, 2026, The Kraft Heinz Company (the "Company") announced that Cory Onell, Executive Vice President and Chief Omnichannel Sales and Asia Emerging Markets Officer, will step down from his role effective June 30, 2026 to pursue other opportunities.

Effective May 29, 2026, Ramesh Ramachandran, CPA, MBA, CMA, resigned as the Chief Accounting Officer of Ocugen, Inc. (the "Company").

Following the resignation of Mr. Ramachandran, who was designated as the Company's principal accounting officer prior to his resignation, on June 3, 2026, Rita Johnson-Greene, MBA, the Company's Chief Financial Officer, was appointed as the Company's principal accounting officer.

Effective May 8, 2026, Huma Qamar, M.D., MPH, CMI, separated from Ocugen, Inc. (the "Company") as its Chief Medical Officer.

On April 26, 2026, Mr. Morrissey was appointed to serve as Chief Executive Officer of the Company on a permanent basis.

On April 26, 2026, Ms. Cox was appointed to serve as Executive Chair on a non-interim basis.

Also stated in this filing

• No changes were made to Mr. Morrissey's compensation or benefits in connection with the appointment to Chief Executive Officer of the Company on a permanent basis.
• No changes were made to Ms. Cox's compensation in connection with the appointment to Executive Chair on a non-interim basis on April 26, 2026.

Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of Jordan Zwick to Board of Directors On June 10, 2026 (the "Effective Date"), the Board of Directors (the "Board") of Palisade Bio, Inc. (the "Company") expanded the size of the Board from five to six directors and appointed Jordan Zwick to the Board.

Further, the Board appointed Mr. Zwick to serve as a member of the Audit Committee of the Board.

Also stated in this filing

• Mr. Zwick will serve until the Company's 2027 annual meeting of stockholders or until such time as his successor is duly elected and qualified or until his earlier death, resignation or removal.
• The Board has determined that Mr. Zwick is independent under the listing standards of the Nasdaq Stock Market and the rules and regulations of the Securities and Exchange Commission (the "SEC").
• The Board also determined that Mr. Zwick satisfied all independence requirements to serve on the Audit Committee.
• The restricted stock units will vest in three equal annual installments over a three-year period.

Protara Therapeutics, Inc. (the "Company") announced that Leonardo Viana Nicacio, M.D., Chief Medical Officer of the Company, resigned from the Company to explore other opportunities, effective as of June 26, 2026.

On June 4, 2026, the board of directors of Purebase Corporation (the "Company") appointed Dr. Amy T. Clemens to serve as the Chief Financial Officer of the Company.

Also stated in this filing

• Dr. Clemens previously served as the Company's Chief Financial Officer from February 2014 to April 2016.
• Dr. Clemens, age 69, has been the co-owner, and chief financial officer and chief operations officer for OPTEC Solutions LLC, a service provider to various US government departments and agencies, since January 2008.

On April 17, 2026, Stephen Gillings' employment as Chief Financial Officer of Purebase Corporation terminated.

On June 18, 2026, Steve Kelsey, M.D., FRCP, FRCPath, informed Revolution Medicines, Inc. (the "Company") of his intent to retire from his employment with the Company effective as of January 4, 2027.

Also stated in this filing

• Dr. Kelsey will transition from his role as the Company's president, research and development to a new position as senior advisor to the chief executive officer effective as of July 1, 2026.
• Upon his retirement from the Company, Dr. Kelsey will be eligible to receive certain benefits under the Company's retirement policy for equity awards.
• The Company currently contemplates appointing Dr. Kelsey to its board of directors (the "Board") effective as of his retirement on January 4, 2027, subject to Board approval.

On June 12, 2026, Tim Walbert, a member of the Board of Directors (the "Board") of Sagimet Biosciences Inc. (the "Company"), tendered his resignation from the Board, effective as of June 12, 2026.

Also stated in this filing

• Mr. Walbert's resignation from the Board was due to other commitments and not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Also stated in this filing

• Retirement of Chief Medical Officer On April 20, 2026, Eduardo Martins, M.D., D.Phil. provided notice to Sagimet Biosciences, Inc. (the "Company") of his retirement from his role as Chief Medical Officer of the Company, effective as of April 20, 2026.
• Dr. Martins will continue to support the Company as an external scientific advisor.

On June 1, 2026, upon recommendation of the Nominating and Governance Committee of the Board of Directors (the "Board") of TechnipFMC plc (the "Company"), the Board elected Eric Mullins to the Board and appointed Mr. Mullins to the Audit Committee of the Board, effective June 1, 2026.

Also stated in this filing

• In connection with the election of Mr. Mullins, the Board will increase its size from nine to ten directors, effective June 1, 2026.
• For his service, Mr. Mullins will receive compensation commensurate with that received by the Company's other non-executive directors as disclosed under the caption "Director Compensation" in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on March 19, 2026, prorated to reflect his length of service in 2026.
• Such compensation is in accordance with the Company's shareholder-approved Director Remuneration Policy.

On June 5th 2026, the Board of Directors of Tradewinds Universal (the "Company") appointed Alan Chang to serve as a member of the Board.

Also stated in this filing

• Mr. Chang is the founder of the Peppermint Hippo brand.
• He will serve until the Company's next annual meeting of shareholders and until his successor is duly elected and qualified, or until his earlier resignation or removal.